CD40 and atherosclerosis: Selective blockade of CD40-TRAF6 interaction preserves CD40-mediated immune functions by maintaining intact CD40-TRAF2/3/5 interactions, thereby overcoming the limitations of long-term CD40 inhibition in atherosclerosis therapy.